「下一代」寡核苷酸疗法初创获1.13亿美元融资,称其候选药效果强于Sarepta
https://www.fiercebiotech.com/biotech/pepgen-raises-113m-to-challenge-sarepta-dmd-build-neuromuscular-and-neurologic-pipeline
https://endpts.com/oxford-spinout-raises-113m-in-bid-to-beat-sareptas-exondys-51-in-dmd-but-will-we-ever-know-if-any-of-the-drugs-work/
赞 (0)